Posaconazole is preferred over fluconazole for prophylaxis of invasive fungal infections in neutropenic patients due to broader spectrum. The pharmacokinetic limitation of the oral suspension form of posaconazole that makes it less reliable in febrile neutropenic patients is:

• A Rapid first-pass metabolism by CYP3A4 reducing plasma concentration below therapeutic levels
• B pH-dependent dissolution requiring acidic gastric pH that is often neutralised by proton pump inhibitors
• C Highly food-dependent absorption (requires high-fat meal for adequate bioavailability) and saturable, dose-limited intestinal absorption ✓
• D High plasma protein binding reducing free drug fraction available for fungicidal activity

Explanation

Posaconazole oral suspension has highly erratic and food-dependent absorption. It requires a high-fat meal or nutritional supplement co-administration for adequate absorption; fasting reduces AUC by >70%. Additionally, absorption is saturable — higher single doses do not proportionally increase plasma levels, requiring divided dosing (TID). In febrile neutropenic patients who are often NPO, receiving mucositis from chemotherapy, or on gastric motility agents, reliable oral suspension absorption cannot be guaranteed. This led to development of the delayed-release tablet (modified release) and intravenous formulations that provide more predictable pharmacokinetics independent of food intake or gastric pH. CYP3A4 metabolism is a drug interaction concern but not the primary absorption limitation.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.